Selective serotonin reuptake inhibitors and bone health

Elizabeth Haney, M. Michael Bliziotes

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Studies demonstrating lower bone mineral density among depressed patients have led to the investigation of antidepressant medications and bone health. It remains unclear whether the depressed state itself or antidepressant treatment is responsible for these findings. Several recent observations support a role for serotonin in bone health. Serotonin transporters have been documented in osteocytes, osteoblasts and osteoclasts. Mice with disruption of the serotonin transporter gene have an osteopenic phenotype. Cohort studies in humans have demonstrated lower bone mineral density, higher rates of bone loss and fracture among those using selective serotonin-reuptake inhibitors compared with those on other antidepressants (primarily tricyclic antidepressants) and those on no antidepressant medication. Areas of future research may include clarifying the role of depression and antidepressant therapy (and the interaction between the two) on bone health, determining potential sources for serotonin in bone cells, identifying mechanisms to explain the impact of serotonin on bone and understanding how serotonin-transporter genetics impact bone.

Original languageEnglish (US)
Pages (from-to)213-222
Number of pages10
JournalFuture Rheumatology
Volume2
Issue number2
DOIs
StatePublished - Apr 2007

Fingerprint

Serotonin Uptake Inhibitors
Antidepressive Agents
Bone and Bones
Serotonin Plasma Membrane Transport Proteins
Health
Serotonin
Bone Density
Osteocytes
Tricyclic Antidepressive Agents
Bone Fractures
Osteoclasts
Osteoblasts
Cohort Studies
Phenotype
Therapeutics
Genes

Keywords

  • Antidepressant medications
  • Bone mineral density
  • Depression
  • Fractures
  • Osteoporosis
  • Selective serotonin uptake inhibitors
  • Serotonin
  • Serotonin transporter

ASJC Scopus subject areas

  • Rheumatology

Cite this

Selective serotonin reuptake inhibitors and bone health. / Haney, Elizabeth; Bliziotes, M. Michael.

In: Future Rheumatology, Vol. 2, No. 2, 04.2007, p. 213-222.

Research output: Contribution to journalArticle

Haney, Elizabeth ; Bliziotes, M. Michael. / Selective serotonin reuptake inhibitors and bone health. In: Future Rheumatology. 2007 ; Vol. 2, No. 2. pp. 213-222.
@article{d6433b0c621c4af98181998fa496a9d1,
title = "Selective serotonin reuptake inhibitors and bone health",
abstract = "Studies demonstrating lower bone mineral density among depressed patients have led to the investigation of antidepressant medications and bone health. It remains unclear whether the depressed state itself or antidepressant treatment is responsible for these findings. Several recent observations support a role for serotonin in bone health. Serotonin transporters have been documented in osteocytes, osteoblasts and osteoclasts. Mice with disruption of the serotonin transporter gene have an osteopenic phenotype. Cohort studies in humans have demonstrated lower bone mineral density, higher rates of bone loss and fracture among those using selective serotonin-reuptake inhibitors compared with those on other antidepressants (primarily tricyclic antidepressants) and those on no antidepressant medication. Areas of future research may include clarifying the role of depression and antidepressant therapy (and the interaction between the two) on bone health, determining potential sources for serotonin in bone cells, identifying mechanisms to explain the impact of serotonin on bone and understanding how serotonin-transporter genetics impact bone.",
keywords = "Antidepressant medications, Bone mineral density, Depression, Fractures, Osteoporosis, Selective serotonin uptake inhibitors, Serotonin, Serotonin transporter",
author = "Elizabeth Haney and Bliziotes, {M. Michael}",
year = "2007",
month = "4",
doi = "10.2217/17460816.2.2.213",
language = "English (US)",
volume = "2",
pages = "213--222",
journal = "Future Rheumatology",
issn = "1758-4272",
publisher = "Future Medicine Ltd.",
number = "2",

}

TY - JOUR

T1 - Selective serotonin reuptake inhibitors and bone health

AU - Haney, Elizabeth

AU - Bliziotes, M. Michael

PY - 2007/4

Y1 - 2007/4

N2 - Studies demonstrating lower bone mineral density among depressed patients have led to the investigation of antidepressant medications and bone health. It remains unclear whether the depressed state itself or antidepressant treatment is responsible for these findings. Several recent observations support a role for serotonin in bone health. Serotonin transporters have been documented in osteocytes, osteoblasts and osteoclasts. Mice with disruption of the serotonin transporter gene have an osteopenic phenotype. Cohort studies in humans have demonstrated lower bone mineral density, higher rates of bone loss and fracture among those using selective serotonin-reuptake inhibitors compared with those on other antidepressants (primarily tricyclic antidepressants) and those on no antidepressant medication. Areas of future research may include clarifying the role of depression and antidepressant therapy (and the interaction between the two) on bone health, determining potential sources for serotonin in bone cells, identifying mechanisms to explain the impact of serotonin on bone and understanding how serotonin-transporter genetics impact bone.

AB - Studies demonstrating lower bone mineral density among depressed patients have led to the investigation of antidepressant medications and bone health. It remains unclear whether the depressed state itself or antidepressant treatment is responsible for these findings. Several recent observations support a role for serotonin in bone health. Serotonin transporters have been documented in osteocytes, osteoblasts and osteoclasts. Mice with disruption of the serotonin transporter gene have an osteopenic phenotype. Cohort studies in humans have demonstrated lower bone mineral density, higher rates of bone loss and fracture among those using selective serotonin-reuptake inhibitors compared with those on other antidepressants (primarily tricyclic antidepressants) and those on no antidepressant medication. Areas of future research may include clarifying the role of depression and antidepressant therapy (and the interaction between the two) on bone health, determining potential sources for serotonin in bone cells, identifying mechanisms to explain the impact of serotonin on bone and understanding how serotonin-transporter genetics impact bone.

KW - Antidepressant medications

KW - Bone mineral density

KW - Depression

KW - Fractures

KW - Osteoporosis

KW - Selective serotonin uptake inhibitors

KW - Serotonin

KW - Serotonin transporter

UR - http://www.scopus.com/inward/record.url?scp=34249291090&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249291090&partnerID=8YFLogxK

U2 - 10.2217/17460816.2.2.213

DO - 10.2217/17460816.2.2.213

M3 - Article

AN - SCOPUS:34249291090

VL - 2

SP - 213

EP - 222

JO - Future Rheumatology

JF - Future Rheumatology

SN - 1758-4272

IS - 2

ER -